Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 13/20 | 0.47 |
| ▸ | AHCY | P23526 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15588438 | 1.00 | STING1 (0.47) | STING1AHCYLMNARAPGEF3GMNN | |
| SCHEMBL16480782 | 1.00 | STING1 (0.47) | STING1AHCYLMNARAPGEF3GMNN | |
| SCHEMBL16480800 | 1.00 | STING1 (0.47) | STING1AHCYLMNARAPGEF3GMNN | |
| SCHEMBL15588449 | 1.00 | STING1 (0.47) | STING1AHCYLMNARAPGEF3GMNN | |
| SCHEMBL17615320 | 1.00 | STING1 (0.47) | STING1AHCYLMNARAPGEF3GMNN | |
| SCHEMBL15588731 | 1.00 | STING1 (0.47) | STING1AHCYLMNARAPGEF3GMNN | |
| SCHEMBL17403964 | 0.89 | STING1 (0.36) | STING1AHCYRXFP1 | |
| SCHEMBL16480802 | 0.87 | STING1 (0.43) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL16480779 | 0.87 | STING1 (0.43) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL16480784 | 0.87 | STING1 (0.43) | STING1LMNARAPGEF3GMNNBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| WO-2014058801-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | SLC28A2, SLC28A1, SLC29A2 | STING1 812/4885AHCY 1017/4885LMNA 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.